Recruiting

Testing a new cancer treatment combined with immunotherapy

Plain-English translation of NCT05492682 on ClinicalTrials.gov ↗ · Source last updated May 2026 · Translation generated June 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This study is testing whether a new medication called , when combined with (a standard immunotherapy), can safely and effectively treat advanced cancers that have specific markers on their cells. The medication is injected directly into tumors or under the skin, and researchers want to see how well it works and what side effects occur. This is one of the first times this treatment combination is being tested in humans.

Many people with advanced cancers stop responding to standard treatments or cannot tolerate them. This trial exists to find out whether this new medication approach can help patients whose cancers have stopped responding to other therapies.

Do you qualify?

You likely qualify if…

you are 18 years of age or older
you have been diagnosed with an advanced or inoperable cancer such as melanoma, triple-negative breast cancer, lung cancer, sarcoma, or colorectal cancer
your cancer has either come back after standard treatment, or you have chosen not to pursue or cannot tolerate standard therapy
you have measurable disease on imaging and a tumor lesion that can be safely biopsied and injected
your liver, kidney, and blood cell function are acceptable based on lab tests
you are willing to use effective contraception during and after the study if you can become pregnant

You likely don't qualify if…

you have received an oncolytic virus treatment or live virus vaccine within the past 4 weeks
you are currently taking high-dose corticosteroids (more than 10 mg of prednisone daily equivalent) or other strong immunosuppressive medications
you are pregnant or breastfeeding
you have received a prior immune checkpoint inhibitor without a 6-week washout period

What participation looks like

You will first receive a low dose of a chemotherapy medication intravenously, followed by injections of the new medication directly into your tumor or under your skin. After that, you will receive the medication in combination with , an immunotherapy drug given through an IV. The study will involve multiple clinic visits for treatment administration, blood tests, imaging scans, and biopsies to monitor how your cancer responds and track any side effects. The duration and exact number of visits will depend on how you respond to treatment.

AI-generated summary from trial data · Jun 4, 2026 · Not medical advice

Trial locations(7 sites)

Germany

Krankenhaus Nordwest, Frankfurt

National Center for Tumor Diseases, Heidelberg

Universitätsklinikum Tübingen, Tübingen

Italy

Istituto di Candiolo Fondazione del Piemonte per l'oncologia IRCCS, Candiolo

IRCCS Istituto Clinico Humanitas, Milan